As shown inFig

As shown inFig. an inhibitory Etizolam constant of 12 M. Finally, siRNA ablation of neutrophil elastase protein production in MDA-MB-231 cells mimicked the I3C-disrupted processing of the 50-kDa cyclin E protein and the indole-induced cell-cycle arrest. Taken together, our results demonstrate that elastase is the first identified specific target protein for I3C and that the direct I3C inhibition of elastase enzymatic activity implicates the potential use of this indole, or related compounds, in targeted therapies of human breast cancers where high elastase levels are correlated with poor prognosis. A critical challenge in controlling breast cancer is the identification of therapeutic brokers that can effectively control the growth of both estrogen-responsive and nonresponsive breast cancer cells with reduced side effects, especially during prolonged treatments. Epidemiological studies show that frequent consumption of certain vegetables is associated with a lower incidence of cancers at various sites (1). For example, the consumption ofBrassica(cruciferous) vegetables, such as cabbage, broccoli, and Brussels sprouts, is usually directly associated with decreased risk of reproductive tissue cancers in humans (2,3) and Etizolam reduced tumor incidence in experimental animals (4). These studies implicate the presence of specific biologically active phytochemicals that represent a largely untapped source of potent chemotherapeutic brokers. One such promising molecule is usually indole-3-carbinol (I3C), a natural compound derived from glycobrassicin inBrassicavegetables, which has been shown to exhibit potent anticarcinogenic properties in a wide range of cancers such as lung, liver, colon, cervical, endometrial, prostate, and breast cancer (57). In addition, out of broad spectrum of analyzed phytochemicals, I3C was 1 of the few that tested positive as a chemopreventative agent in a panel of short-term bioassays relevant to carcinogen-induced DNA damage, tumor initiation and promotion, and oxidative stress (8). We have discovered that I3C induces a G1cell-cycle arrest of both estrogen-responsive and unresponsive human breast malignancy cells (912) that occurs with a concomitant inhibition of expression or activity of CDK6 and CDK2, respectively, and with a marked decrease in endogenous retinoblastoma (Rb) protein phosphorylation (9,11,12). I3C down-regulates CDK6 transcription by disrupting the Etizolam conversation between Sp1 transcription factors with a Sp1-Ets composite DNA element in the CDK6 promoter (11). In estrogen-responsive breast malignancy cells, I3C suppresses estrogen responsiveness (13,14), down-regulates expression of estrogen receptor- (13), and synergizes with the antiproliferative effects of tamoxifen, an anti-estrogen widely used in breast cancer therapies (10). In nontumorigenic human mammary epithelial cells, I3C can induce the ATM signaling pathway impartial of DNA damage to stabilize an active p53 tumor suppressor protein (15). I3C can suppress invasion and migration of human breast malignancy cells (16) and stimulate IFN- receptor production and IFN- responsiveness (17). In other types of human reproductive cancer cells, I3C has been shown to have strong antiproliferative effects (5,6,1821), and it alters immune function in vivo (22). Despite compelling evidence for the potent anticancer properties of this indole, the direct cellular target(s) of I3C that play a central role in the striking cell-cycle effects of this phytochemical have not been uncovered. Eukaryotic cellular growth relies on the activation of cyclin/cyclin-dependent kinase (CDK) protein complexes that function at specific stages of the cell cycle (23). Many breast tumors exhibit elevated levels of cyclin E and cyclin D, which implicate the loss of cell-cycle control by deregulation of the G1phase of the cell cycle (24,25). Both high-molecular-weight and lower-molecular-weight TRIB3 forms of cyclin E have been detected in mammalian cells. Interestingly, many highly proliferative tissues, such as that of metastatic breast cancer,.